WO2012058588A3 - Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci - Google Patents

Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci Download PDF

Info

Publication number
WO2012058588A3
WO2012058588A3 PCT/US2011/058378 US2011058378W WO2012058588A3 WO 2012058588 A3 WO2012058588 A3 WO 2012058588A3 US 2011058378 W US2011058378 W US 2011058378W WO 2012058588 A3 WO2012058588 A3 WO 2012058588A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoconjugates
binding molecules
novel egfr
egfr
novel
Prior art date
Application number
PCT/US2011/058378
Other languages
English (en)
Other versions
WO2012058588A2 (fr
WO2012058588A4 (fr
Inventor
Julianto Setiady
Peter U. Park
Lingyun Rui
Thomas Chittenden
Gillian Payne
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Priority to NZ609619A priority Critical patent/NZ609619A/en
Priority to MX2013004761A priority patent/MX2013004761A/es
Priority to JP2013536880A priority patent/JP5828901B2/ja
Priority to EA201390472A priority patent/EA201390472A1/ru
Priority to CN2011800550576A priority patent/CN103298489A/zh
Priority to SG2013029335A priority patent/SG189929A1/en
Priority to CA2815277A priority patent/CA2815277A1/fr
Priority to KR1020137013346A priority patent/KR20140008308A/ko
Priority to AU2011320314A priority patent/AU2011320314B2/en
Priority to EP11837192.1A priority patent/EP2632490A4/fr
Priority to BR112013010544A priority patent/BR112013010544A2/pt
Publication of WO2012058588A2 publication Critical patent/WO2012058588A2/fr
Publication of WO2012058588A3 publication Critical patent/WO2012058588A3/fr
Publication of WO2012058588A4 publication Critical patent/WO2012058588A4/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne de nouveaux agents anticancéreux, comprenant, de façon non limitative, des anticorps et des immunoconjugués, qui se lient au récepteur EGF. L'invention concerne également des méthodes d'utilisation de ces agents, anticorps ou immunoconjugués, notamment des méthodes d'inhibition de la croissance tumorale.
PCT/US2011/058378 2010-10-29 2011-10-28 Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci WO2012058588A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
NZ609619A NZ609619A (en) 2010-10-29 2011-10-28 Novel egfr-binding molecules and immunoconjugates thereof
MX2013004761A MX2013004761A (es) 2010-10-29 2011-10-28 Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
JP2013536880A JP5828901B2 (ja) 2010-10-29 2011-10-28 新規ｅｇｆｒ結合分子およびその免疫抱合体
EA201390472A EA201390472A1 (ru) 2010-10-29 2011-10-28 Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
CN2011800550576A CN103298489A (zh) 2010-10-29 2011-10-28 新型egfr结合分子及其免疫偶联物
SG2013029335A SG189929A1 (en) 2010-10-29 2011-10-28 Novel egfr-binding molecules and immunoconjugates thereof
CA2815277A CA2815277A1 (fr) 2010-10-29 2011-10-28 Nouvelles molecules se liant au recepteur egf et immunoconjugues de celles-ci
KR1020137013346A KR20140008308A (ko) 2010-10-29 2011-10-28 신규한 egfr-결합 분자 및 이의 면역컨쥬게이트
AU2011320314A AU2011320314B2 (en) 2010-10-29 2011-10-28 Novel EGFR-binding molecules and immunoconjugates thereof
EP11837192.1A EP2632490A4 (fr) 2010-10-29 2011-10-28 Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci
BR112013010544A BR112013010544A2 (pt) 2010-10-29 2011-10-28 moléculas de ligação ao egfr e imunoconjugados das mesmas

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40849710P 2010-10-29 2010-10-29
US61/408,497 2010-10-29
US201161477086P 2011-04-19 2011-04-19
US61/477,086 2011-04-19

Publications (3)

Publication Number Publication Date
WO2012058588A2 WO2012058588A2 (fr) 2012-05-03
WO2012058588A3 true WO2012058588A3 (fr) 2012-10-18
WO2012058588A4 WO2012058588A4 (fr) 2012-12-06

Family

ID=45994816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/058378 WO2012058588A2 (fr) 2010-10-29 2011-10-28 Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci

Country Status (13)

Country Link
US (3) US8790649B2 (fr)
EP (1) EP2632490A4 (fr)
JP (2) JP5828901B2 (fr)
KR (1) KR20140008308A (fr)
CN (1) CN103298489A (fr)
AU (1) AU2011320314B2 (fr)
BR (1) BR112013010544A2 (fr)
CA (1) CA2815277A1 (fr)
EA (1) EA201390472A1 (fr)
MX (1) MX2013004761A (fr)
NZ (1) NZ609619A (fr)
SG (1) SG189929A1 (fr)
WO (1) WO2012058588A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008118970A2 (fr) 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
EA201390472A1 (ru) 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
CA2825255C (fr) 2011-01-24 2021-05-18 Ym Biosciences Inc. Anticorps selectifs des cellules presentatrices des recepteurs de egf a haute densite
CA2842860A1 (fr) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Proteines se liant a sur dirigees contre erbb3
CN104066481A (zh) * 2011-11-21 2014-09-24 伊缪诺金公司 利用egfr抗体细胞毒性剂缀合物治疗抗egfr疗法的肿瘤的方法
EP2793940B1 (fr) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Protéines substitutives de liaison
EP2804631B1 (fr) 2012-01-20 2021-03-17 i2 Pharmaceuticals, Inc. Surrobody conjugués
WO2013172961A1 (fr) * 2012-05-14 2013-11-21 Genentech, Inc. Compositions et méthodes destinées à diagnostiquer et à traiter des tumeurs
US9944707B2 (en) 2012-05-17 2018-04-17 Sorrento Therapeutics, Inc. Antibodies that bind epidermal growth factor receptor (EGFR)
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
AU2013326881B2 (en) 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
ES2809501T3 (es) * 2013-07-05 2021-03-04 Formation Biologics Inc Conjugados de anticuerpo de EGFR
US20150079079A1 (en) * 2013-09-13 2015-03-19 Wake Forest University Health Sciences Methods and Compositions for Treatment of Chlamydial Infection and Related Diseases and Disorders
KR20160138177A (ko) * 2014-03-21 2016-12-02 애브비 인코포레이티드 항-ｅｇｆｒ 항체 및 항체 약물 접합체
WO2015184403A2 (fr) * 2014-05-30 2015-12-03 Henlius Biotech Co., Ltd. Anticorps anti-récepteurs du facteur de croissance épidermique (egfr)
MA42561A (fr) 2014-09-02 2018-04-25 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicament
TWI757759B (zh) 2014-09-03 2022-03-11 美商免疫原公司 細胞毒性苯并二氮呯衍生物
EP3189057A1 (fr) 2014-09-03 2017-07-12 ImmunoGen, Inc. Dérivés de benzodiazépine cytotoxique
MA40968A (fr) * 2014-10-31 2017-10-04 Formation Biologics Inc Polythérapie à base d'anticorps anti-egfr
KR20180021176A (ko) 2015-06-29 2018-02-28 이뮤노젠 아이엔씨 시스테인 조작된 항체의 콘주게이트
CA3014934A1 (fr) 2016-03-04 2017-09-08 JN Biosciences, LLC Anticorps anti-tigit
KR102652827B1 (ko) 2016-06-08 2024-04-01 프레시전 인코포레이티드 Cd33 특이적 키메라 항원 수용체
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
CN106362161A (zh) * 2016-08-29 2017-02-01 苏州普罗达生物科技有限公司 一种小分子cd33抗体多肽与长春新碱偶联的结合物
EP3544983A2 (fr) 2016-11-23 2019-10-02 Immunogen, Inc. Sulfonation sélective de dérivés de benzodiazépine
KR20240110082A (ko) 2017-02-28 2024-07-12 이뮤노젠 아이엔씨 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
AU2018281316B2 (en) * 2017-06-07 2024-05-30 Precigen, Inc. Expression of novel cell tags
CN107496933B (zh) * 2017-08-21 2019-12-24 山东新华制药股份有限公司 一种用于治疗胰腺癌的抗体药物偶联物及其制备方法
WO2019070856A1 (fr) * 2017-10-03 2019-04-11 Precision Biosciences, Inc. Peptides de récepteur de facteur de croissance épidermique modifiés destinés à être utilisés dans des cellules génétiquement modifiées
TW202413360A (zh) 2017-12-28 2024-04-01 美商伊繆諾金公司 苯二氮平衍生物
LT3958977T (lt) 2019-04-26 2023-12-27 Immunogen, Inc. Kamptotecino dariniai
CN114127108A (zh) * 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
US11820824B2 (en) 2020-06-02 2023-11-21 Arcus Biosciences, Inc. Antibodies to TIGIT

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06319396A (ja) * 1993-05-07 1994-11-22 Japan Tobacco Inc 抗ウイルス抗体を産生する植物及びその作出方法
US20050142635A1 (en) * 1991-04-25 2005-06-30 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6 receptor
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
US20070264253A1 (en) * 2004-03-19 2007-11-15 Meilin Liu Human Anti-Epidermal Growth Factor Receptor Antibody
US7780964B2 (en) * 2003-12-22 2010-08-24 Glaxo Group Limited Immunoglobulins which bind NOGO

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
CZ282603B6 (cs) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
EP0563475B1 (fr) 1992-03-25 2000-05-31 Immunogen Inc Conjugués d'agents ciblés et de dérivés du CC-1065
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
DE69529649T2 (de) 1994-03-17 2003-12-18 Merck Patent Gmbh Anti-egfr einkettige fvs und anti-egfr antikoerper
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1033406A4 (fr) 1997-10-27 2005-03-09 Sumitomo Electric Industries Inducteur pour la production d'un anticorps specifique de l'antigene, vecteur d'expression contenant le gene requis a cette fin, et procede pour induire la production de l'anticorps specifique de l'antigene
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
ATE349438T1 (de) 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
AU2001239857B9 (en) 2000-02-25 2006-07-27 Duke University Anti-EGFRvIII SCFVS with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
KR20030074839A (ko) 2001-02-19 2003-09-19 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 항-ｅｇｆｒ 항체
CA2447139C (fr) * 2001-05-11 2013-11-19 Ludwig Institute For Cancer Research Proteines de liaison specifiques et utilisations associees
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CN1966525A (zh) 2001-06-13 2007-05-23 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
GB0122914D0 (en) 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
CA2494310A1 (fr) * 2002-08-01 2004-02-12 Immunomedics, Inc. Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
EP2281577B1 (fr) * 2003-05-14 2016-11-16 ImmunoGen, Inc. Composition constituee de conjuges de medicaments
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR101531400B1 (ko) 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
CA2542239C (fr) * 2003-10-16 2014-12-30 Micromet Ag Element de liaison au cd3, desimmunise multispecifique
EP1697741A4 (fr) 2003-12-04 2008-02-13 Xencor Inc Procedes pour produire des proteines variantes presentant une plus grande concentration en chaine hote et compositions de celles-ci
ATE501173T1 (de) * 2003-12-04 2011-03-15 Abbott Biotherapeutics Corp Anti-ip-10-antikörper
CA2555503C (fr) * 2004-02-16 2018-03-27 Micromet Ag Molecules de liaison moins immunogenes
CN104774931B (zh) 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
MX2007012817A (es) 2005-04-15 2007-12-12 Immunogen Inc Eliminacion de poblacion celular heterogenea o mezclada en tumores.
US8101183B2 (en) * 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
CN101646690B (zh) 2006-08-11 2013-10-23 默沙东公司 抗il-17a抗体
US20090258442A1 (en) 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
CN104013956B (zh) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
EP2109947B1 (fr) 2007-02-05 2016-04-13 Telefonaktiebolaget LM Ericsson (publ) Estimation de charge à l'aide d'une puissance de liaison montante programmée
WO2008098145A1 (fr) 2007-02-07 2008-08-14 University Of Washington Procédés de modulation des réponses des lymphocytes b spécifiques des antigènes
CA2676049C (fr) * 2007-03-01 2018-04-10 Symphogen A/S Compositions d'anticorps recombinants diriges contre le recepteur du facteur de croissance epidermique
US7892777B2 (en) 2007-07-17 2011-02-22 The Regents Of The University Of Michigan Methods for measuring whether a treatment affects RPTP-κ activity
US20110256142A1 (en) 2007-09-06 2011-10-20 Genmab A/S Novel methods and antibodies for treating cancer
CN101932333A (zh) * 2007-12-26 2010-12-29 瓦西尼斯公司 抗c35抗体联合疗法和方法
US20090269343A1 (en) 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
US8236319B2 (en) 2008-04-30 2012-08-07 Immunogen, Inc. Cross-linkers and their uses
EP2276506A4 (fr) 2008-04-30 2014-05-07 Immunogen Inc Conjugués puissants et coupleurs hydrophiles
WO2010009124A2 (fr) 2008-07-15 2010-01-21 Genentech, Inc. Conjugués de dérivés d’anthracycline, procédé de préparation associé et utilisation comme composés antitumoraux
RU2540146C2 (ru) 2008-08-29 2015-02-10 Симфоген А/С Композиции рекомбинантных антител против рецептора эпидермального фактора роста
US20110217302A1 (en) 2008-10-10 2011-09-08 Emergent Product Development Seattle, Llc TCR Complex Immunotherapeutics
WO2010055950A1 (fr) 2008-11-17 2010-05-20 財団法人ヒューマンサイエンス振興財団 Nouvelle thérapie de ciblage du cancer à l'aide d'un complexe de substance capable de se lier spécifiquement à un facteur constituant de stroma cancéreux et composé anti-tumeur
CN103003424B (zh) * 2010-05-18 2015-05-13 株式会社医学生物学研究所 结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体
EA201390472A1 (ru) 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
CN104066481A (zh) 2011-11-21 2014-09-24 伊缪诺金公司 利用egfr抗体细胞毒性剂缀合物治疗抗egfr疗法的肿瘤的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142635A1 (en) * 1991-04-25 2005-06-30 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6 receptor
JPH06319396A (ja) * 1993-05-07 1994-11-22 Japan Tobacco Inc 抗ウイルス抗体を産生する植物及びその作出方法
US7780964B2 (en) * 2003-12-22 2010-08-24 Glaxo Group Limited Immunoglobulins which bind NOGO
US20070264253A1 (en) * 2004-03-19 2007-11-15 Meilin Liu Human Anti-Epidermal Growth Factor Receptor Antibody
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 5 June 2008 (2008-06-05), "Mus musculus IgM anti-Dns hybridoma VDJ4 region of J558 family mRNA.", XP003030112, Database accession no. 15225.1. *
DATABASE GENBANK [online] 7 March 2004 (2004-03-07), "Mus musculus isolate 217 immunoglobulin light chain variable region mRNA, partial cds.", XP003030113, Database accession no. AY208307.1. *
KIMURA ET AL.: "Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild -type or mutant epidermal growth factor receptor.", CANCER SCI., vol. 98, no. 8, 2007, pages 1275 - 80, XP055107100 *
LAUX ET AL.: "Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies.", BR J CANCER., vol. 94, no. 1, 2006, pages 85 - 92, XP002477032 *
LI ET AL.: "Skin toxicities associated with epidermal growth factor receptor inhibitors.", TARGET ONCOL., vol. 4, no. 2, 2009, pages 107 - 119, XP055107113 *
MUTSAERS ET AL.: "Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.", CLIN CANCER RES., vol. 15, no. 7, 2009, pages 2397 - 405, XP055107111 *
OCVIRK.: "Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream.", JOURNAL RADIOLOGY AND ONCOLOGY, vol. 44, no. 4, 22 September 2010 (2010-09-22), pages 265 - 266, XP055107106 *
RABEN ET AL.: "The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy In Lung Cancer.", CLINICAL CANCER RESEARCH, vol. 11, 2005, pages 795 - 805, XP008068460 *
STEINER ET AL.: "Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild.type and Mutated Epidermal Growth Factor Receptor.", CLIN CANCER RES., vol. 13, no. 5, 2007, pages 1540 - 1551, XP055107096 *

Also Published As

Publication number Publication date
EA201390472A1 (ru) 2014-02-28
WO2012058588A2 (fr) 2012-05-03
MX2013004761A (es) 2013-08-27
US9125896B2 (en) 2015-09-08
JP2014500711A (ja) 2014-01-16
CN103298489A (zh) 2013-09-11
EP2632490A2 (fr) 2013-09-04
CA2815277A1 (fr) 2012-05-03
AU2011320314A1 (en) 2013-04-11
BR112013010544A2 (pt) 2016-08-02
US20120156217A1 (en) 2012-06-21
US20140099308A1 (en) 2014-04-10
AU2011320314B2 (en) 2015-08-06
NZ609619A (en) 2015-05-29
JP5828901B2 (ja) 2015-12-09
WO2012058588A4 (fr) 2012-12-06
US20160060345A1 (en) 2016-03-03
SG189929A1 (en) 2013-06-28
JP2015143271A (ja) 2015-08-06
US8790649B2 (en) 2014-07-29
EP2632490A4 (fr) 2014-10-22
KR20140008308A (ko) 2014-01-21

Similar Documents

Publication Publication Date Title
WO2012058588A3 (fr) Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci
WO2012019024A3 (fr) Molécules se liant à her3 et leurs immunoconjugués
MY173839A (en) Cd37-binding molecules and immunoconjugates thereof
WO2012058592A3 (fr) Molécules non antagonistes se liant au récepteur egf et immunoconjugués de celles-ci
MX2019009654A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
WO2013048883A3 (fr) Anticorps anti-erbb3 et leurs utilisations
WO2010037041A3 (fr) Agents se liant aux récepteurs frizzled et leurs utilisations
WO2012162561A3 (fr) Complexes plurispécifiques multivalents et monovalents, et leurs utilisations
PH12014502419A1 (en) Specific binding proteins and uses thereof
WO2012012759A3 (fr) Anticorps-antigènes antitumoraux et méthodes d'utilisation correspondantes
WO2013021279A3 (fr) Anticorps fortement galactosylés
PH12014501108A1 (en) Anti-il-36r antibodies
PH12017500864A1 (en) Anti-notch1 antibodies
GB201020995D0 (en) Biological materials and uses thereof
WO2012109373A3 (fr) Traitement de l'arthrose et de la douleur
WO2011136911A3 (fr) Anticorps anti-erbb3
WO2011123785A3 (fr) Agents de liaison aux récepteurs frizzled et leurs utilisations
IN2015DN00636A (fr)
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
WO2011041319A3 (fr) Protéines de liaison spécifiques et leurs utilisations
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
EA201290243A1 (ru) Хиназолиновые соединения
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
TN2013000040A1 (en) Antibodies for epidermal growth factor receptor 3 (her3)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11837192

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2011320314

Country of ref document: AU

Date of ref document: 20111028

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2815277

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013536880

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/004761

Country of ref document: MX

Ref document number: 201390472

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137013346

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2011837192

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: A201305697

Country of ref document: UA

Ref document number: 2011837192

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013010544

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013010544

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130429